title: Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China.
abstract: BACKGROUND
  In recent years, the carcinoma of the breast threatens to women's health heavily. Invasion and metastasis is the main reason that results in the patients death.
  
  
  OBJECTIVE
  A prospective study is made in the center hospital of zhengzhou, in order to approach the expression of nm23, MMP-2 (Matrix metallo-proteinase-2), TIMP-2 (it's tissue-inhibitor of the metalloproteinase-2) in the breast neoplasm and the relationship with invasion and metastasis.
  
  
  METHODS
  This study applied the immunohistochemistry technique SP method
  
  
  RESULTS
  In fibroadenoma, ductal carcinoma in situ and invasive ductal carcinoma of the breast 4 groups, the positive immunostaining rate of nm23, MMP-2 and TIMP-2 have significant difference among 4 groups (p < 0.05). In the breast invasive ductal carcinoma, the expression of nm23 and TIMP-2 decreased or the expression of MMP-2 increased
  
  
  CONCLUSIONS
  This suggested that invasion and metastasis is ability of the neoplasm. MMP-2 in the breast ductal carcinoma in situ appears of high expression and this suggested that the positive expression of this onco-proteins was the early incident in the genetic course of the breast cancer The unite detection of nm23, MMP-2 and TIMP-2 expression would contribute to the early diagnosis and prognostic assessment of the carcinoma of the breast.
authors.affiliation: Department of Pathology, The Chinese Medical Team, the Center of Zhengzhou City Hospital, China.
authors.forename: Shen
authors.initials: S
authors.lastname: Peihong
authors.forename: Franklin
authors.initials: F
authors.lastname: Perry
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000201:enzymology; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000201:enzymology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000201:enzymology; D002681:China; D005260:Female; D018226:Fibroadenoma / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D053504:Matrix Metalloproteinases, Membrane-Associated / Q000627:therapeutic use*; D054778:NM23 Nucleoside Diphosphate Kinases; D009362:Neoplasm Metastasis; D009701:Nucleoside-Diphosphate Kinase / Q000378:metabolism*; D011446:Prospective Studies; D019716:Tissue Inhibitor of Metalloproteinase-2
chemical_list: D000970:Antineoplastic Agents; D054778:NM23 Nucleoside Diphosphate Kinases; D019716:Tissue Inhibitor of Metalloproteinase-2; C517938:NME1 protein, human; D009701:Nucleoside-Diphosphate Kinase; D053504:Matrix Metalloproteinases, Membrane-Associated; D020780:Matrix Metalloproteinase 9